Clinical Trial Update: iCAT for Recurrent/Refractory/HR Solid Tumors

View source ↗

Summary

A completed clinical trial evaluating iCAT for recurrent/refractory/high-risk solid tumors in pediatric patients, including Neuroblastoma, Wilms tumor, and Soft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Soft Tissue Sarcoma
• Wilms Tumor

Drugs mentioned

• iCAT

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Pediatric Solid Tumor, Sarcoma | Status: COMPLETED